Profil de l'entreprise · Healthcare

Sino Biopharmaceutical Ltd

1177 · Hong Kong
Pays / Région
Hong Kong
Date d'introduction en bourse
29 septembre 2000
Effectif
22 838
Buffett Score
79/100
Solide
Capitalisation99,38 Md HKD
Chiffre d'affaires (TTM)33,7 Md HKD
EBITDA10,45 Md HKD
Marge nette7,09 %
ROE14,07 %
PER (TTM)37,2
PER prévisionnel17,39
PEG0,72
BPA0,00 HKD
Rendement du dividende1,84 %
Fourchette sur 52 semaines4,14 HKD – 8,33 HKD

Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Historique

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.

Position dans le secteur

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.

Pas encore d'analyse sur cette valeur dans votre langue.